Constructing a diversified stock portfolio

If I had to name the top 50 assets to build the background of a bullet proof dividend stock portfolio consisting of wonderful businesses showing long term earnings and dividend growth over decades, I’d certainly put Swiss pharma giant Roche into that group.

Yes, there are Tech Giants that have a huge impact on the way we live, work and communicate, and sure, in a diversified portfolio there has to be an exposure to businesses like Alphabet, Amazon, Alibaba, Facebook, Microsoft and/or Apple. There is no doubt that these companies belong to the winners of the future.

But there is also a group of businesses providing you with an ever increasing passive income stream ready to reinvest and use the Power of the Domino Effect.

In order to establish Passive Income Sources and make use of the Compound Effect, one wants to have a look at stocks of enterprises one does not have to babysit, that keep rewarding their investors just for holding patiently their stakes for decades collecting escalating cash flow streams.

We all know the Dividend Aristocrats of the Standard & Poors Index, companies that raised their divideds for at least 25 years in a row. Businesses like Coca Cola, 3M, PepsiCo or Johnson & Johnson.

And here in Europe, we have wonderful businesses too, like Nestlé, Novartis and of course there is Roche.

A Swiss “Dividend Aristocrat”

Roche is a leader in diagnostics, cancer treatment and has an immensly strong position in biotechnology.

Roche sports a market cap of roughly Swiss francs (CHF) 300 Bn (one CHF corresponds to roughly USD 1.1), has revenues in the amout of over CHF 61.5 Bn with CHF 22.5 Bn in operating profits (numbers per 31.12.2019 2019).

Well, let’s face the fact: it’s just a massive business with a durable economic moat.

Roche has raised its dividend for 32 consecutive years and the company is committed to keep increasing its shareholder distributions in the future.

With a payout ratio between 50 and 60 % and annual growth rates in the mid single digit range coupled with a rock solid strong balance sheet, Roche is an interesting company to consider investing in.

A look at my Roche’s cash dividend returns

In 2011, I acquired 18 non-voting shares of Roche at a price of around CHF 135. Today, the stock price stands at around CHF 310.

Let’s have a look at the development of the yearly cash returns compared to my initial investment of CHF 135 in 2011 (yield at cost). The deduction of the Swiss witholding tax of 35 % resp. 15 % has hereby to be considered. When there is a double taxation treaty with the country of the investor, twenty percentage points can be reimbursed to that investor to lower the tax rate to 15 %.

From 2011 to 2020 the dividend payments (in CHF; gross amounts) from Roche were as follows: 6.80, 7.35, 7.80, 8.00, 8.10, 8.20, 8.30, 8.70, 9.00.

In the last ten years, I collected CHF 61.50 (net after taxes) resp. over 45 % of the invested amount in dividends.

These are quite decent returns so far. I don’t even factor in the book gain of 230 % or dividend (re-) investments.

My dividend yields at cost (after witholding taxes) increased from slightly over 4 % to currently 5.6 %. A few years, and one has a “high yield stock” but with a much more conservative and attractive basis in contrast to oil majors that are considerably less stable.

The interesting thing with Roche is that the stock rarely is overvalued. In fact, over long time periods the shares are trading at a discount compared to its peers such as Johnson & Johnson for example.

This is to some surprise in my view given the global footprint of Roche and its tremendously strong market position. But of course there also lies the window of opportunity.

I expect Roche to generate an EPS of 20 CHF in the current year and paying out a dividend of at least CHF 9.10 next year (for 2020). A starting gross dividend yield of slightly below 3 % acquired for a P/E ratio of 16 looks like a fair price to consider for a wonderful business.

Disclaimer
You are responsible for your own investment and financial decisions. This article is not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action.